These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 19920790)

  • 1. Inhibiting the renin-angiotensin system in patients with type 1 diabetes: is it worth it?
    Duka I; Bakris G
    Pol Arch Med Wewn; 2009 Nov; 119(11):692-3. PubMed ID: 19920790
    [No Abstract]   [Full Text] [Related]  

  • 2. Diabetes complications and the renin-angiotensin system.
    Perkins BA; Aiello LP; Krolewski AS
    N Engl J Med; 2009 Jul; 361(1):83-5. PubMed ID: 19571288
    [No Abstract]   [Full Text] [Related]  

  • 3. Renoprotective effects of renin-angiotensin-aldosterone system blockers in type 2 diabetes: demystifying multiple treatment comparisons in a network meta-analysis.
    Catalá-López F
    Diabetologia; 2012 Sep; 55(9):2547-8; author reply 2549-50. PubMed ID: 22729654
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibition of the renin-angiotensin system: added value in reducing cardiovascular and renal risk?
    Marshall SM
    Diabet Med; 2004 Jan; 21(1):1-3. PubMed ID: 14706047
    [No Abstract]   [Full Text] [Related]  

  • 5. Renin-angiotensin-aldosterone system blockade and urinary albumin excretion in community-based patients with Type 2 diabetes: the Fremantle Diabetes Study.
    Fegan PG; Davis WA; Kamber N; Sivakumar S; Beilby J; Davis TM
    Diabet Med; 2011 Jul; 28(7):849-55. PubMed ID: 21231957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal and retinal effects of enalapril and losartan in type 1 diabetes.
    Katavetin P; Katavetin P
    N Engl J Med; 2009 Oct; 361(14):1410-1; author reply 1411. PubMed ID: 19802919
    [No Abstract]   [Full Text] [Related]  

  • 7. [Renin inhibition and the kidney].
    Ecder T
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():28-31. PubMed ID: 20019474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dual blockade of the renin-angiotensin system].
    Andersen NH; Mogensen CE
    Ugeskr Laeger; 2004 Oct; 166(43):3799-803. PubMed ID: 15544108
    [No Abstract]   [Full Text] [Related]  

  • 9. Renin angiotensin system (RAS) blockade and diabetic microvascular complications in the eye and kidney.
    Bilous R
    Prim Care Diabetes; 2008 Dec; 2(4):201-2. PubMed ID: 18760685
    [No Abstract]   [Full Text] [Related]  

  • 10. Renoprotective effects of renin-angiotensin-system inhibitors.
    Parving HH; Rossing P
    Lancet; 2006 Mar; 367(9514):898-9; author reply 900-2. PubMed ID: 16546532
    [No Abstract]   [Full Text] [Related]  

  • 11. [Debate concerning the optimal blockage of the renin-angiotensin system].
    Choukroun G
    Nephrol Ther; 2010 Jan; 6 Spec No 1():H1-9. PubMed ID: 20129454
    [No Abstract]   [Full Text] [Related]  

  • 12. [Control of arterial pressure in diabetic nephropathy].
    Luño J; García de Vinuesa S
    Nefrologia; 2001; 21(3):240-5. PubMed ID: 11471304
    [No Abstract]   [Full Text] [Related]  

  • 13. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal dosing of renin-angiotensin-aldosterone system blockers for renal protection: a solved issue?
    Laverman GD; Bakker SJ; Navis GJ
    Diabetologia; 2009 Jun; 52(6):1217-8. PubMed ID: 19294362
    [No Abstract]   [Full Text] [Related]  

  • 15. Renal and retinal effects of enalapril and losartan in type 1 diabetes.
    Tamsma JT
    N Engl J Med; 2009 Oct; 361(14):1410; author reply 1411. PubMed ID: 19797291
    [No Abstract]   [Full Text] [Related]  

  • 16. [Type 2 diabetes and nephropathy--new studies, new treatment strategies?].
    Os I; Stenehjem A; Høieggen A; Draganov B; Jenssen T; Holdaas H
    Tidsskr Nor Laegeforen; 2002 Apr; 122(9):918-20. PubMed ID: 12082835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prediction, screening and treatment of renal complications of diabetes].
    Marre M; Larger E
    Rev Prat; 2001 Oct; 51(16):1769-75. PubMed ID: 11795120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Can progression to terminal renal insufficiency be avoided in diabetic nephropathy?].
    Luño J; Valderrábano F
    An Med Interna; 1998 Nov; 15(11):567-71. PubMed ID: 9882851
    [No Abstract]   [Full Text] [Related]  

  • 19. Are angiotensin-converting enzyme inhibitors the renal protective antihypertensive drugs of choice?
    Bauer JH
    Curr Opin Nephrol Hypertens; 1995 Sep; 4(5):427-31. PubMed ID: 8564447
    [No Abstract]   [Full Text] [Related]  

  • 20. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.